ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "juvenile idiopathic arthritis (JIA)"

  • Abstract Number: 2696 • 2019 ACR/ARP Annual Meeting

    Long-Term Efficacy and Safety of Сanakinumab in Children with Systemic Juvenile Idiopathic Arthritis

    Ekaterina Alexeeva1, Rina Denisova 2, Tatyana Dvoryakovskaya 2, Ksenia Isaeva 2, Ivan Kriulin 2, Alina Alshevskaya 3 and Andrey Moskalev 3, 1National Medical Research Center of Children`s Health, Moscow, Russia, 2NMRCCH, Moscow, Russia, 3Biostatistics and Clinical Trials Center, Novosibirsk, Russia

    Background/Purpose: Canakinumab (CAN) is an efficacious option for treatment of systemic juvenile idiopathic arthritis (sJIA). However, it is still disputable whether long-term therapy is efficacious…
  • Abstract Number: 804 • 2019 ACR/ARP Annual Meeting

    STING-associated Vasculopathy with Onset in Infancy (SAVI Syndrome) Can Mimic Juvenile Idiopathic Arthritis

    Jose Luis Tandaipan1, Mireia Lopez Corbeto 2 and Estefania Moreno Ruzafa 3, 1Hospital Universitari Mutua Terrassa, Terrassa, Spain, 2Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain, 3Hospital Universitari Vall d'Hebron, Barcelona, Spain

    Background/Purpose: Gain-of-function mutations in TMEM173 encoding STING (Stimulator of Interferon Genes) underlie a novel type I INF termed SAVI syndrome. It is characterized by a…
  • Abstract Number: 2699 • 2019 ACR/ARP Annual Meeting

    Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab

    Najima Mwase 1, Theresa Hennard 2, Joseph McDonald 3, Amy Cassedy 4, Onengiya Harry 3 and Sheila Angeles-Han5, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, 3Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, 4Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, 5Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cinicinnati

    Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is the most common extra-articular manifestation of JIA, leading to ocular complications and blindness when not adequately treated. First…
  • Abstract Number: 915 • 2019 ACR/ARP Annual Meeting

    Development and Initial Validation of the Systemic JADAS, a New Composite Disease Activity Score for Systemic Juvenile Idiopathic Arthritis

    Jessica Tibaldi1, Yasser El Miedany 2, Pryiankar Pal 3, Soamarat Vilaiyuk 4, Raju Khubchandani 5, Manuela Pardeo 6, Tapas Kumar Sabui 7, Sujata Sawhney 8, Ricardo Russo 9, Flavio Sztajnbok 10, Rolando Cimaz 11, Francesca Minoia 12, Motasem O. Alsuweiti 13, Ekaterina Alexeeva 14, Mikhail Kostik 15, Maria Cristina Maggio 16, Sulayman Al Mayouf 17, Claudia Saad 18, Giovanni Conti 19, Romina Gallizzi 20, Adele Civino 21, Masaki Shimizu 22, Enrico Felici 23, Angela Pistorio 24, Nicolino Ruperto 25, Alessandro Consolaro 26 and Angelo Ravelli 27, 1IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genoa, Italy, 2Ain Shams University, Cairo, Egypt, 3Institute of Child Health, Kolkata, India, 4Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 5Jaslok Hospital and Research Center, Mumbai, India, 6Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 7R G Kar Medical College, Kolkata, Kolkata, India, 8Department of pediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, New Delhi, India, 9Hospital de Pediatría Garrahan, Buenos Aires, Argentina, 10Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 11University Hospital Meyer, Florence, Italy, 12Clinica De Marchi Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, 13Queen Rania Children's Hospital, Amman, Jordan, 14National Medical Research Center of Children`s Health, Moscow, Russia, 15Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, 16Università di Palermo, Dipartimento G. D'Alessandro, Palermo, Italy, 17King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, 18Hospital das Clínicas - Botucatu Medicine University, UNESP, Botucatu, Brazil, 19AOU G Martino, Messina, Italy, 20Azienda Ospedaliera Universitaria Gaetano Martino, Messina, Messina, Italy, 21Pediatric Rheumatology “Vito Fazzi” Hospital, Lecce, Lecce, Italy, 22Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa, Japan, 23SS Antonio e Biagio e Cesare Arrigo" Hospital, Alessandria, Italy, 24IRCCS Istituto Giannina Gaslini, Genova, Italy, 25Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 26Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy, 27IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy

    Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) has gained increasing popularity for the measurement of the level of disease activity in patients with juvenile…
  • Abstract Number: 2701 • 2019 ACR/ARP Annual Meeting

    Frequency of Juvenile Idiopathic Arthritis (JIA) Subgroups and JIA-associated Uveitis Among JIA Patients Admitted to Referral Pediatric Rheumatology Clinics In TurkEy: A Retrospective Study, JUPITER

    Sezgin Sahin 1, Ceyhun Acari 2, Hafize Emine Sonmez 3, Fatma Zehra Kilic 4, Erdal Sag 5, Hatice Adiguzel Dundar 6, Amra Adrovic 7, Selcan Demir 3, Kenan Barut 8, Yelda Bilginer 9, Betul Sozeri 10, Erbil Unsal 6, Seza Ozen 11 and Ozgur Kasapcopur12, 1Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Istanbul, Turkey, 2Dokuz Eylul University, School of Medicine, Izmir, Turkey, 3Hacettepe University, School of Medicine, Ankara, Turkey, 4Umraniye Training and Research Hospital, Istanbul, 5Hacettepe University, Ankara, Turkey, 6Dokuz Eylul University, School of Medicie, Izmir, Turkey, 7Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, 8Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, İstanbul, Istanbul, Turkey, 9Division of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University, Ankara, Turkey, 10University of Health Sciences , Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, Istanbul, Turkey, 11Hacettepe University Hospital, Ankara, Turkey, 12Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a chronic childhood arthritis with onset before age of 16 and has a significant degree of morbidity that negatively…
  • Abstract Number: 916 • 2019 ACR/ARP Annual Meeting

    Development and Initial Validation of the MS Score for Diagnosis of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis

    Francesca Minoia1, Francesca Bovis 2, Sergio Davì 3, AnnaCarin Horne 4, Michel Fischbach 5, Michael Frosch 6, Adam Huber 7, Marija Jelusic 8, Sujata Sawhney 9, Deborah McCurdy 10, Clovis Artur Silva 11, Donato Rigante 12, Erbil Unsal 13, Nicolino Ruperto 14, Alberto Martini 15, Randy Cron 16 and Angelo Ravelli 15, 1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy, 2Università degli Studi di Genova, Genoa, Italy, 3IRCCS Istituto Giannina Gaslini, Genova, Italy, 4Karolinska University Hospital, Stockholm, Sweden, 5Hopital Universitaire Hautepierre, Strasbourg, France, 6School of Medicine Witten/Herdecke University, Datteln, Germany, 7IWK Health Centre, Halifax, NS, Canada, 8University of Zagreb, Zagreb, Croatia, 9Sir Ganga Ram Hospital, New Delhi, India, 10University of California, MDCC 12-430, 10833 Le Conte Ave, Los Angeles, 90095, CA, USA, Los Angeles, 11Childrens’ Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, 12Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 13Dokuz Eylul University, School of Medicie, Izmir, Turkey, 14Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 15IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, 16University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Macrophage activation syndrome (MAS) is the most severe complication of systemic juvenile idiopathic arthritis (sJIA) and its adult equivalent, adult-onset Still’s disease (AOSD).  Because…
  • Abstract Number: 2702 • 2019 ACR/ARP Annual Meeting

    Patients’ and Parents’ Perception of Disease and Its Impact on Life in Juvenile Idiopathic Arthritis: Results from Multinational Virtual Focus Groups by the OMERACT JIA Working Group

    Alessandra Alongi1, Serana Calandra 1, Susan Thornhill 2, Jennifer Stinson 3, Jen Horonjeff 4, Daniel Horton 5, Alessandro Consolaro 6 and Esi Morgan 7, 1Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, 2Thornhill Associates, Hermosa Beach, USA, Hermosa Beach, 3The Hospital for Sick Children, and University of Toronto, Toronto, Canada, Toronto, 4Columbia University Medical Center, New York, USA, New York, 5Division of Pediatric Rheumatology, Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, Institute for Health, Health Care Policy and Aging Research, Rutgers Biomedical and Health Sciences, New Brunswick, 6Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy, 7Cincinnati Children’s Hospital, University of Cincinnati, Cinncinati, OH

    Background/Purpose: The OMERACT Juvenile Idiopathic Arthritis Core Set Working Group formed in 2015 as an international initiative to revise the existing Core Set with relevant…
  • Abstract Number: 1125 • 2019 ACR/ARP Annual Meeting

    Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs

    Joe Zhuo1, Ying Bao 2, Qian Xia 2, Aarti Rao 3, Niyati Sharma 3, Xue Han 4 and Robert Wong 5, 1Bristol-Myers Squibb, Princeton, NJ, 2Bristol-Myers Squibb, Lawrenceville, NJ, 3Mu Sigma, Bangalore, India, 4Bristol-Myers Squibb Company, Princeton, NJ, 5Bristol-Myers Squibb, Princeton

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is a common, chronic rheumatic disease of childhood that carries substantial economic impact on patients (pts) and families1. The objective…
  • Abstract Number: 2704 • 2019 ACR/ARP Annual Meeting

    Injection Fear in Juvenile Idiopathic Arthritis Patients Using Injectable Medications

    Kathleen Collins1, Anava Wren 2 and Tzielan Lee 2, 1Stanford University School of Medicine, Palo Alto, CA, 2Stanford University School of Medicine, Palo Alto

    Background/Purpose: Injectable medications are frequently used to treat Juvenile Idiopathic Arthritis (JIA).  Fear of pain and needle fear have been identified as barriers to injectable…
  • Abstract Number: 170 • 2019 ACR/ARP Annual Meeting

    Evaluating an Illustrated Storybook for Children with Juvenile Idiopathic Arthritis

    Jimin Lee1, Dennis Newhook 2, Kaylee Eady 2 and Roman Jurencak 1, 1Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, 2CHEO Research Institute, Ottawa, ON, Canada

    Background/Purpose: While juvenile idiopathic arthritis (JIA) is a common pediatric rheumatic disease, there is a lack of available child-friendly patient education materials. An illustrated storybook…
  • Abstract Number: 1174 • 2019 ACR/ARP Annual Meeting

    Prevalence of Subclinical Sacroiliitis in Young Patients with Inflammatory Bowel Disease Revealed by Entero-MRI

    Teresa Giani1, Marco Di Maurizio 2, Paolo Lionetti 2, Azzurra Bernardini 2, Giovanna Ferrara 1, Viola Filistrucchi 2 and Rolando Cimaz 3, 1Anna Meyer Children University Hospital, Florence, Italy, 2A. Meyer Children University Hospital, Florence, Italy, 3Meyer Children's Hospital in Florence, Florence, Italy

    Background/Purpose: Sacroiliitis is one of the extraintestinal manifestations associated with inflammatory bowel disease (IBD), and may be underdiagnosed especially in the pediatric age. MR-enterography (Entero-MRI)…
  • Abstract Number: 2705 • 2019 ACR/ARP Annual Meeting

    Profiling Behavioral and Psychological Symptoms in Children with Spondyloarthritis and Polyarthritis

    Anne McHugh1, Avis Chan 2, Carolyn Herrera 2, Margo Thienemann 2 and Jennifer Frankovich 2, 1Stanford University School of Medicine, Palo Alto, CA, 2Stanford University School of Medicine, Palo Alto

    Background/Purpose: Mental health disorders are thought to be common in patients with rheumatic disease, but studies examining behavioral issues in patients with juvenile idiopathic arthritis…
  • Abstract Number: 2378 • 2018 ACR/ARHP Annual Meeting

    Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category

    Nicola Ruperto1, Hermine I. Brunner2, Gabriel Vega-Cornejo3, Alberto Berman4, Rubén J. Cuttica5, Francisco Ávila-Zapata6, Michael Henrickson7, Daniel J Kingsbury8, John F. Bohnsack9, Thomas Lutz10, Nadina E Rubio-Pérez11, Valeria Gerloni12, Xiaohui Li13, Marleen Nys14, Robert Wong13, Alberto Martini15 and Daniel J Lovell16, 1Istituto Giannina Gaslini - Clinica Pediatrica e Reumatologia, Genoa, Italy, 2Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Clinica de Reumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, 4Centro Médico Privado de Reumatología, Tucumán, Argentina, 5Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, 6Star Medica Hospital, Merida, Yucatán, Mexico, 7Cincinnati Children’s Medical Center, Cincinnati, OH, 8Randall Children’s Hospital at Legacy Emanuel, Portland, OR, 9University of Utah School of Medicine, Salt Lake City, UT, 10Pediatric Rheumatology, University Hospital, Center for Pediatric and Adolescent Medicine / Clinic 1, Heidelberg, Germany, 11Universidad Autónoma de Nuevo León, Monterrey Nuevo León, Mexico, 12Istituto Gaetano Pini, Milan, Italy, 13Bristol-Myers Squibb, Princeton, NJ, 14Bristol-Myers Squibb, Braine L’Alleud, Belgium, 15Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy, 16Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: The effect of biologic DMARDs on different juvenile idiopathic arthritis (JIA) categories is poorly understood. In patients (pts) with JIA aged 2–17 years (y),…
  • Abstract Number: 2389 • 2018 ACR/ARHP Annual Meeting

    Evaluating Disease Activity Outcomes for Juvenile Idiopathic Arthritis across the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN)

    Emily A. Smitherman1, Bin Huang2, Ronald M. Laxer3, C. April Bingham4, Cagri Yildirim-Toruner5, Beth Gottlieb6, Jennifer Weiss7, Tzielan Lee8, Sheetal S. Vora9, Jon (Sandy) Burnham10, Julia Harris11, Judyann C. Olson12, Mileka Gilbert13, Michelle Batthish14, Michael Shishov15, Dustin Fleck16 and Esi Morgan1, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 4Penn State Health Children's Hospital, Hershey, PA, 5Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, 6Pediatric Rheumatology PTD, Cohen Children's Medical Center of New York, Lake Success, NY, 7Hackensack University Medical Center, Hackensack, NJ, 8Pediatric Rheumatology, Stanford University, Palo Alto, CA, 9Pediatric Rheumatology, Levine Children's Hospital, Charlotte, NC, 10Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 11Children's Mercy - Kansas City, Kansas City, MO, 12Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, 13Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, 14Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, 15Phoenix Children's Hospital, Phoenix, AZ, 16Pediatric Rheumatology, University of Michigan, Brighton, MI

    Background/Purpose: It is widely accepted that the treatment goal for juvenile idiopathic arthritis (JIA) is remission. PR-COIN, a quality improvement collaborative comprised of pediatric rheumatology…
  • Abstract Number: 2391 • 2018 ACR/ARHP Annual Meeting

    Methotrexate Polyglutamates As an Evaluation Tool for Appropriate Dosage of Oral Methotrexate Administration in Pediatric Patients

    Nami Okamoto1, Kosuke Shabana2, Yasuo Nakagishi3, Kenichi Nishimura4, Mao Mizuta5, Yuka Okura6, Masaki Shimizu5, Hiroyuki Wakiguchi7, Junko Yasumura8 and Masaaki Mori9, 1Pediatrics, Osaka Medical College, Takatsuki, Japan, 2Department of Pediatrics, Osaka Medical College, Takatsuki, Japan, 3Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan, 4Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 5Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan, 6Department of Pediatrics, KKR Sapporo Medical Center, Sapporo, Japan, 7Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan, 8Department of Pediatrics, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan, 9Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

    Background/Purpose: Since MTX metabolism varies depending on age and dosage, we need to know optimal MTX administration method in children. We performed multi-center prospective study…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology